Advertisement
ACAD vs RYTM
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACAD is a StrongBuy and RYTM is a StrongBuy.
ACAD in +6.90% Uptrend, rising for three consecutive days on October 20, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ACAD advanced for three days, in 189 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ACAD's RSI Indicator exited the oversold zone, 15 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 65%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on ACAD as a result. In 71 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
The Moving Average Convergence Divergence (MACD) for ACAD just turned positive on October 15, 2026. Looking at past instances where ACAD's MACD turned positive, the stock continued to rise in 33 of 46 cases over the following month. The odds of a continued upward trend are 72%.
ACAD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The 10-day moving average for ACAD crossed bearishly below the 50-day moving average on September 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACAD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
The Aroon Indicator for ACAD entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 28 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 76 (best 1 - 100 worst), indicating slightly worse than average price growth. ACAD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.678) is normal, around the industry mean (2.973). P/E Ratio (8.987) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (4.168) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 85 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 87 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACAD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
RYTM's RSI Oscillator ascends from oversold territory
The RSI Oscillator for RYTM moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 17 similar instances when the indicator left oversold territory. In 15 of the 17 cases the stock moved higher. This puts the odds of a move higher at 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 47 of 54 cases where RYTM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on RYTM as a result. In 62 of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for RYTM just turned positive on October 20, 2026. Looking at past instances where RYTM's MACD turned positive, the stock continued to rise in 41 of 49 cases over the following month. The odds of a continued upward trend are 84%.
Following a +4.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where RYTM advanced for three days, in 237 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
RYTM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RYTM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.
The Aroon Indicator for RYTM entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 22 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. RYTM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: RYTM's P/B Ratio (60.774) is slightly higher than the industry average of (2.973). P/E Ratio (-29.135) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (27.548) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
ACAD | RYTM | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 3 | 10 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 82 Overvalued | 89 Overvalued | |
PROFIT vs RISK RATING 1..100 | 87 | 22 | |
SMR RATING 1..100 | 28 | 100 | |
PRICE GROWTH RATING 1..100 | 76 | 62 | |
P/E GROWTH RATING 1..100 | 85 | 25 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ACAD's Valuation (82) in the Biotechnology industry is in the same range as RYTM (89). This means that ACAD’s stock grew similarly to RYTM’s over the last 12 months.
RYTM's Profit vs Risk Rating (22) in the Biotechnology industry is somewhat better than the same rating for ACAD (87). This means that RYTM’s stock grew somewhat faster than ACAD’s over the last 12 months.
ACAD's SMR Rating (28) in the Biotechnology industry is significantly better than the same rating for RYTM (100). This means that ACAD’s stock grew significantly faster than RYTM’s over the last 12 months.
RYTM's Price Growth Rating (62) in the Biotechnology industry is in the same range as ACAD (76). This means that RYTM’s stock grew similarly to ACAD’s over the last 12 months.
RYTM's P/E Growth Rating (25) in the Biotechnology industry is somewhat better than the same rating for ACAD (85). This means that RYTM’s stock grew somewhat faster than ACAD’s over the last 12 months.
| ACAD | RYTM | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 65% | 1 day ago 88% |
| Stochastic ODDS (%) | 1 day ago 72% | 1 day ago 87% |
| Momentum ODDS (%) | 1 day ago 73% | 1 day ago 83% |
| MACD ODDS (%) | 1 day ago 72% | 1 day ago 84% |
| TrendWeek ODDS (%) | 1 day ago 75% | 1 day ago 81% |
| TrendMonth ODDS (%) | 1 day ago 70% | 1 day ago 75% |
| Advances ODDS (%) | 3 days ago 75% | 3 days ago 81% |
| Declines ODDS (%) | 10 days ago 68% | 10 days ago 73% |
| BollingerBands ODDS (%) | 1 day ago 68% | 1 day ago 87% |
| Aroon ODDS (%) | 1 day ago 72% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ACAD’s FA Score shows that 1 FA rating(s) are green while RYTM’s FA Score has 2 green FA rating(s).
- ACAD’s FA Score: 1 green, 4 red.
- RYTM’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ACAD’s TA Score shows that 5 TA indicator(s) are bullish while RYTM’s TA Score has 6 bullish TA indicator(s).
- ACAD’s TA Score: 5 bullish, 4 bearish.
- RYTM’s TA Score: 6 bullish, 2 bearish.
Price Growth
ACAD (@Biotechnology) experienced а +3.04% price change this week, while RYTM (@Biotechnology) price change was +3.33% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.
Reported Earning Dates
ACAD is expected to report earnings on Nov 04, 2026.
RYTM is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Biotechnology (-1.17% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
RYTM and
Correlation & Price change
A.I.dvisor indicates that over the last year, RYTM has been loosely correlated with SRRK. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if RYTM jumps, then SRRK could also see price increases.
| Ticker / NAME | Correlation To RYTM | 1D Price Change % | ||
|---|---|---|---|---|
| RYTM | 100% | +2.57% | ||
| SRRK - RYTM | 46% Loosely correlated | -2.42% | ||
| VIR - RYTM | 44% Loosely correlated | -1.32% | ||
| ACAD - RYTM | 41% Loosely correlated | +0.59% | ||
| BEAM - RYTM | 41% Loosely correlated | -1.13% | ||
| XNCR - RYTM | 40% Loosely correlated | +2.70% | ||
More | ||||